Viewing Study NCT00603356


Ignite Creation Date: 2025-12-24 @ 11:35 PM
Ignite Modification Date: 2026-02-22 @ 4:36 AM
Study NCT ID: NCT00603356
Status: COMPLETED
Last Update Posted: 2011-09-27
First Post: 2007-12-26
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Phase I Study of OSI-930 and Erlotinib in Cancer Tumors
Sponsor: Astellas Pharma Inc
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module